Calprotectin in synovial fluid (LFT)

The Lyfstone test is a method for the risk stratification of infection in suspected periprosthetic joint infection (PJI) patients by determination of Calprotectin levels in human synovial fluid samples.

Ruling out infection is the number one priority for the orthopaedic surgeon. PJI can lead to additional surgeries, revision, possibly amputation, and increased patient discomfort.

When encountering patients with painful joints, the orthopaedic consultant must consider the possibility for infection. Rapidly ruling out infection creates the opportunity for same-day diagnostics for evidence based patient flow decisions.

Lyfstone® Calprotectin for Synovial Fluid is a novel PJI biomarker. Calprotectin (CLP) is abundantly present in neutrophils. Presence of neutrophils is a hallmark of PJI, and a massive release of CLP occurs upon encounter with pathogens.

Elevated levels of CLP have been demonstrated to hold excellent diagnostic precision for both acute and chronic PJI, with excellent negative prediction value (NPV) for ruling out infection in suspected PJI patients.